Summary
Introducing UZPRUVO, a groundbreaking biosimilar to ustekinumab and the very first of its kind to grace the French pharmaceutical landscape. This innovative medication comes in two convenient dosages, 45 mg and 90 mg, elegantly packaged in a pre-filled syringe that’s ready for action—no fuss, just relief. UZPRUVO carries the weight of possibilities as a monoclonal antibody crafted to inhibit the interleukins 12 and 23, paving the way for enhanced treatment options for psoriasis and other inflammatory conditions. Elaborate in its application, UZPRUVO is not only intended for the stubborn patches of psoriasis that affect both adults and children aged six and above, but it also lends a hand to those grappling with psoriatic arthritis and Crohn’s disease in adults. Yet, for young ones tipping the scales at less than 60 kg, the dosage dilemmas emerge; the 45 mg formulation requires a transition to the original STELARA in vial form, ensuring a tailored treatment approach. Imagine the ease of a pre-filled syringe, designed for effortless, subcutaneous injections. Patients or caregivers can administer UZPRUVO into the upper thigh, abdomen, or upper arm, making it as simple as pie to integrate into one’s daily routine. Just remove the protective cap, press down on the syringe’s plunger to release the medicine, and watch the needle retract into its safe guard—a symphony of simplicity in each administration. UZPRUVO proudly stands as a beacon for health enthusiasts; it’s available with a 65% reimbursement option, accompanied by a prescription marked as an exception. Compounding its allure, the drug is listed by the ANSM, ensuring its place among the prestigious biosimilars approved for tackling psoriasis, rheumatism, and inflammatory bowel diseases. With each injection, you embark upon a journey of skin health, reclaiming comfort and confidence with the promise of UZPRUVO. The price, a notable €1,257.19, reflects both the investment in wellbeing and the cutting-edge nature of this medical marvel. As it holds firm in the realm of dermatology, gastroenterology, and rheumatology, UZPRUVO is poised to transform lives, one injection at a time.
Original Source: www.vidal.fr
